EUCTR2018-003281-14-ES进行中（未招募）1 期
Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in Molecular Response (ResToP)
Fundación CRIS contra el Cáncer0 个研究点目标入组 80 人开始时间: 2019年11月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male or female patients = 18 years of age.
- •2. ECOG Performance Status of 0, 1, or 2.
- •3. Patient with diagnosis of BCR-ABL positive and Ph+ CML-Chronic Phase.
- •4. Patient has achieved MR4 for one year with TKI treatment confirmed by RT-qPCR lab assessment at screening after a previous TKI treatment´s discontinuation.
- •5. Patients who are able to take oral therapy
- •6. Adequate end organ function as defined by:
- •a. Direct bilirubin = 1.5 x ULN
- •b. SGOT(AST) and SGPT(ALT) = 2.5 x ULN,
- •c. Serum lipase and amylase = 1.5 x ULN,
- •d. Alkaline phosphatase = 2.5 x ULN,
- •e. Serum creatinine = 1.5 x ULN.
- •7. Patients must have the following electrolyte values = LLN limits or corrected to within normal limits with supplements prior to the first dose of study medication: a. Potassium, b. Magnesium, c. Total calcium (corrected for serum albumin)
- •8. Patients must have normal marrow function as defined below:
- •a. Absolute Neutrophil Count (ANC) = 1.5 x 109/L,
- •b. Platelets = 100 x 109/L.
- •c. Hemoglobin > 9 g/dL.
- •9. Patients with preexisting, well-controlled diabetes can be included.
- •10. Have normal QTcF interval on screening ECG evaluation, defined as QTcF of = 450 ms in males or = 470 ms in females.
- •11. Have a negative pregnancy test documented prior to enrollment (for females of childbearing potential). diately.
- •12. Be willing and able to comply with scheduled visits and study procedures.
- •13. Patients with the ability to comprehend and sign the informed consent
- •14. Written informed consent obtained prior to any screening procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. Prior accelerate phase, blast crisis or autologous or allogenic transplant
- •2. Patients with known atypical transcript. An atypical transcript is defined by the presence of any transcript in the absence of the major transcripts b3a2 (e14a2) and b2a2 (e13a2) or p210 protein.
- •3. CML treatment resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V) detected if a testing was done in the past (there is no requirement to perform mutation testing at study entry if it was not done in the past).
- •4. Are taking medications with a known risk of torsades de pointes (Annex 5).
- •5. Patient ever attempted to permanently discontinue TKI treatment.
- •6. Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g., uncontrolled diabetes (defined as HbA1c > 9%), uncontrolled infection).
- •7. Have clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
- •a. Any history of MI, unstable angina, cerebrovascular accident, or TIA.
- •b. Any history of peripheral vascular infarction, including visceral infarction.
- •c. Any revascularization procedure, including the placement of a stent.
- •d. Congestive heart failure (NYHA class III or IV) within 6 months prior to enrollment, or LVEF less than lower limit of normal, per local institutional standards, within 6 months prior to enrollment.
- •e. History of clinically significant (as determined by the treating physician) atrial arrhythmia or any history of ventricular arrhythmia.
- •f. Venous thromboembolism, including deep venous thrombosis or pulmonary embolism, within 6 months prior to enrollment.
- •8. Have uncontrolled hypertension (diastolic blood pressure > 90 mmHg; systolic > 150 mmHg). Patients with hypertension should be under treatment on study entry to effect blood pressure control.
- •9. Have a history of alcohol abuse.
- •10. History of acute pancreatitis within 1 year prior to study entry or past medical history of chronic pancreatitis.
- •11. Have malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drug.
- •12. Known presence of a significant congenital or acquired bleeding disorder unrelated to cancer.
- •13. Have a history of another malignancy, other than cervical cancer in situ or no metastatic basal cell or squamous cell carcinoma of the skin; the exception is if patients have been disease-free for at least 5 years, and are deemed by the investigator to be at low risk for recurrence of that malignancy.
- •14. Have undergone major surgery (with the exception of minor surgical procedures, such as catheter placement) within 14 days prior to first dose of ponatinib.
- •15. Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks of Day 1.
- •16. Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry. See Annex 6 for a list of these medications. This list may not be comprehens
研究者
相似试验
进行中（未招募）
1 期
Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in Molecular Response (ResToP)Chronic myelogenous leukemiaMedDRA version: 21.0Level: LLTClassification code: 10009012Term: Chronic myelogenous leukemia Class: 10029104CTIS2023-508993-27-00Fundacion Cris De Investigacion Para Vencer El Cancer80
进行中（未招募）
1 期
Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, who had previously Achieved a Deep Molecular Response with ImatinibEUCTR2017-004565-27-ESFUNDACIÓN TEÓFILO HERNANDO11
进行中（未招募）
不适用
Research study, conducted in patients with chronic hepatitis B, during treatment with nucleos(t)ide analogues (NA), with the aim to assess the effect of the administration of peginterferon alfa-2a (PEG-IFN) for 48 weeks, on the improvement of treatment responses.EUCTR2012-000080-25-ITROCHE
进行中（未招募）
不适用
Multicenter, Open-Label, Single Arm Phase II Clinical Trial of Dasatinib in the Treatment of Systemic Mastocytosis (SM) - Dasatinib and systemic mastocytosisEUCTR2008-006183-11-ITIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
进行中（未招募）
1 期
A Study to Investigate the Efficacy of Venetoclax Plus Lenalidomide and Dexamethasone in Participants with Newly Diagnosed t(11;14)-Positive Multiple MyelomaMedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864Multiple MyelomaEUCTR2018-003287-31-ESAbbVie Deutschland GmbH & Co. KG40